Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S. Grønberg BH, et al. Among authors: hjelde hh. J Clin Oncol. 2009 Jul 1;27(19):3217-24. doi: 10.1200/JCO.2008.20.9114. Epub 2009 May 11. J Clin Oncol. 2009. PMID: 19433683 Clinical Trial.
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.
Grønberg BH, Sundstrøm S, Kaasa S, Bremnes RM, Fløtten O, Amundsen T, Hjelde HH, Plessen Cv, Jordhøy M. Grønberg BH, et al. Among authors: hjelde hh. Eur J Cancer. 2010 Aug;46(12):2225-34. doi: 10.1016/j.ejca.2010.04.009. Epub 2010 May 12. Eur J Cancer. 2010. PMID: 20471248 Clinical Trial.
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.
Helbekkmo N, Sundstrøm SH, Aasebø U, Brunsvig PF, von Plessen C, Hjelde HH, Garpestad OK, Bailey A, Bremnes RM; Norwegian Lung Cancer Study Group. Helbekkmo N, et al. Among authors: hjelde hh. Br J Cancer. 2007 Aug 6;97(3):283-9. doi: 10.1038/sj.bjc.6603869. Epub 2007 Jun 26. Br J Cancer. 2007. PMID: 17595658 Free PMC article. Clinical Trial.
[Recurrence and survival after surgical treatment of lung cancer].
Hjelde H, Sundstrøm S, Ødegård A, Hatlinghus S, Abusland AB, Haaverstad R. Hjelde H, et al. Tidsskr Nor Laegeforen. 2010 Jan 14;130(1):25-8. doi: 10.4045/tidsskr.09.0689. Tidsskr Nor Laegeforen. 2010. PMID: 20094119 Free article. Norwegian.
Increase in curative treatment and survival of lung cancer in Norway 2001-2016.
Solberg S, Nilssen Y, Brustugun OT, Grimsrud TK, Haram PM, Helbekkmo N, Helland Å, Hjelde HH, Jakobsen B, Møller B, Petersen M, Strand TE, Wahl SGF, Aanerud M, Fjellbirkeland L. Solberg S, et al. Among authors: hjelde hh. Eur J Epidemiol. 2019 Oct;34(10):951-955. doi: 10.1007/s10654-019-00536-z. Epub 2019 Jul 16. Eur J Epidemiol. 2019. PMID: 31313073